ODTX · Odyssey Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| TPG GP A, LLC 10% Owner | ▲ Buy | Open Market | 3,690,146 Shares held | 5/11/2026 | View profile |
| Dimension Capital II, L.P. Director | ▲ Buy | Open Market | 3,333,516 Shares held | 5/8/2026 | View profile |
| Li Nan (LN) | ▲ Buy | Open Market | 3,333,516 Shares held | 5/11/2026 | View profile |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 1,014,851 Shares held | 5/11/2026 | View profile |
| Glick Gary D See Remarks | ▼ Sell | Other | 415,973 Shares held | 5/11/2026 | View profile |
| Haas Jason Director | ▲ Buy | Open Market | 62,908 Shares held | 5/8/2026 | View profile |
| LEIDEN JEFFREY M Executive Chairman | ▼ Sell | Tax Withholding | 31,644 Shares held | 5/11/2026 | View profile |
| Chu Shelley | ▲ Buy | Open Market | 11,111 Shares held | 5/11/2026 | View profile |
| Opipari Anthony W. See Remarks | ▼ Sell | Tax Withholding | 7,502 Shares held | 5/11/2026 | View profile |
Transaction History
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 20,582 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 133,333 | $2.4M | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Open Market | 438 | $8K | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 200,000 | $3.6M | 5/11/2026 |
| Opipari Anthony W. | ▼ Sell | Tax Withholding | 4 | $72 | 5/11/2026 |
| Li Nan (LN) | ▲ Buy | Open Market | 1,111,111 | $20.0M | 5/11/2026 |
| TPG GP A, LLC | ▼ Sell | Other | 1,880,497 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Open Market | 1,065 | $19K | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 204,658 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Open Market | 277 | $5K | 5/11/2026 |
| TPG GP A, LLC | ▲ Buy | Open Market | 1,388,889 | $25.0M | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 59,692 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 49,850 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▲ Buy | Open Market | 222,222 | $4.0M | 5/11/2026 |
| TPG GP A, LLC | ▼ Sell | Other | 2,351 | $42K | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 191,541 | — | 5/11/2026 |
| LEIDEN JEFFREY M | ▲ Buy | Option Exercise | 2,963 | — | 5/11/2026 |
| Chu Shelley | ▲ Buy | Open Market | 11,111 | $200K | 5/11/2026 |
| TPG GP A, LLC | ▼ Sell | Other | 423,111 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 683,817 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 255,823 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 61,762 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 463,106 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 139,366 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 78,656 | — | 5/11/2026 |
| LEIDEN JEFFREY M | ▼ Sell | Tax Withholding | 17 | $306 | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 273,527 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 474,048 | — | 5/11/2026 |
| Opipari Anthony W. | ▼ Sell | Other | 6,965 | — | 5/11/2026 |
| Li Nan (LN) | ▼ Sell | Other | 1,709,543 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 118,512 | — | 5/11/2026 |
| LEIDEN JEFFREY M | ▼ Sell | Other | 28,698 | — | 5/11/2026 |
| Opipari Anthony W. | ▲ Buy | Option Exercise | 541 | — | 5/11/2026 |
| Glick Gary D | ▼ Sell | Other | 27,386 | — | 5/11/2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | ▼ Sell | Other | 166,168 | — | 5/11/2026 |
| Haas Jason | ▲ Buy | Open Market | 1,000 | $20K | 5/8/2026 |
| Dimension Capital II, L.P. | ▲ Buy | Open Market | 1,111,111 | $20.0M | 5/8/2026 |
| Dimension Capital II, L.P. | ▼ Sell | Other | 1,709,543 | — | 5/8/2026 |
| LEIDEN JEFFREY M | ▲ Buy | Open Market | 5,000 | $100K | 5/8/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026
Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.